GoodRx (NASDAQ:GDRX) Shares Gap Down – Time to Sell?
by Michael Walen · The Markets DailyShares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $2.58, but opened at $2.50. GoodRx shares last traded at $2.5750, with a volume of 965,560 shares trading hands.
Analyst Ratings Changes
A number of research analysts recently commented on GDRX shares. Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Citigroup dropped their target price on GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a report on Friday, January 9th. Weiss Ratings restated a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Jefferies Financial Group downgraded GoodRx to a “hold” rating in a research report on Thursday. Finally, Barclays assumed coverage on shares of GoodRx in a research report on Monday, December 8th. They set an “underweight” rating and a $3.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, GoodRx presently has an average rating of “Hold” and a consensus price target of $4.73.
Read Our Latest Report on GDRX
GoodRx Stock Performance
The firm has a market capitalization of $868.94 million, a P/E ratio of 28.44, a P/E/G ratio of 0.98 and a beta of 1.45. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. The firm has a 50-day moving average price of $2.75 and a two-hundred day moving average price of $3.67.
GoodRx (NASDAQ:GDRX – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $196.03 million during the quarter, compared to analysts’ expectations of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The company’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business earned $0.08 EPS. On average, analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.
Institutional Investors Weigh In On GoodRx
A number of institutional investors and hedge funds have recently bought and sold shares of GDRX. XTX Topco Ltd raised its stake in GoodRx by 281.2% in the 2nd quarter. XTX Topco Ltd now owns 272,273 shares of the company’s stock worth $1,356,000 after acquiring an additional 200,852 shares during the last quarter. LSV Asset Management acquired a new position in shares of GoodRx in the second quarter valued at about $1,900,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of GoodRx by 16.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock valued at $8,324,000 after purchasing an additional 236,896 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of GoodRx in the second quarter worth about $981,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of GoodRx during the second quarter worth about $58,000. 63.77% of the stock is owned by institutional investors.
About GoodRx
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.